🎉 M&A multiples are live!
Check it out!

Adverum Biotechnologies Valuation Multiples

Discover revenue and EBITDA valuation multiples for Adverum Biotechnologies and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Adverum Biotechnologies Overview

About Adverum Biotechnologies

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.


Founded

2006

HQ

United States of America
Employees

121

Website

adverum.com

Financials

LTM Revenue $0.7M

LTM EBITDA -$124M

EV

-$8.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Adverum Biotechnologies Financials

Adverum Biotechnologies has a last 12-month revenue of $0.7M and a last 12-month EBITDA of -$124M.

In the most recent fiscal year, Adverum Biotechnologies achieved revenue of $3.6M and an EBITDA of -$118M.

Adverum Biotechnologies expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Adverum Biotechnologies valuation multiples based on analyst estimates

Adverum Biotechnologies P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $3.6M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$151M -$118M XXX XXX XXX
EBITDA Margin -Infinity% -3287% XXX XXX XXX
Net Profit -$146M -$155M XXX XXX XXX
Net Margin -Infinity% -4293% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Adverum Biotechnologies Stock Performance

As of April 15, 2025, Adverum Biotechnologies's stock price is $3.

Adverum Biotechnologies has current market cap of $71.4M, and EV of -$8.6M.

See Adverum Biotechnologies trading valuation data

Adverum Biotechnologies Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$8.6M $71.4M XXX XXX XXX XXX $-5.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Adverum Biotechnologies Valuation Multiples

As of April 15, 2025, Adverum Biotechnologies has market cap of $71.4M and EV of -$8.6M.

Adverum Biotechnologies's trades at -12.1x LTM EV/Revenue multiple, and 0.1x LTM EBITDA.

Analysts estimate Adverum Biotechnologies's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Adverum Biotechnologies and 10K+ public comps

Adverum Biotechnologies Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$8.6M XXX XXX XXX
EV/Revenue -2.4x XXX XXX XXX
EV/EBITDA 0.1x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Adverum Biotechnologies Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Adverum Biotechnologies Valuation Multiples

Adverum Biotechnologies's NTM/LTM revenue growth is -100%

Adverum Biotechnologies's revenue per employee for the last fiscal year averaged $30K, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Adverum Biotechnologies's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Adverum Biotechnologies's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Adverum Biotechnologies and other 10K+ public comps

Adverum Biotechnologies Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -3287% XXX XXX XXX XXX
EBITDA Growth -21% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $30K XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 1387% XXX XXX XXX XXX
R&D Expenses to Revenue 2158% XXX XXX XXX XXX
Opex to Revenue 3544% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Adverum Biotechnologies Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Adverum Biotechnologies M&A and Investment Activity

Adverum Biotechnologies acquired  XXX companies to date.

Last acquisition by Adverum Biotechnologies was  XXXXXXXX, XXXXX XXXXX XXXXXX . Adverum Biotechnologies acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Adverum Biotechnologies

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Adverum Biotechnologies

When was Adverum Biotechnologies founded? Adverum Biotechnologies was founded in 2006.
Where is Adverum Biotechnologies headquartered? Adverum Biotechnologies is headquartered in United States of America.
How many employees does Adverum Biotechnologies have? As of today, Adverum Biotechnologies has 121 employees.
Who is the CEO of Adverum Biotechnologies? Adverum Biotechnologies's CEO is Dr. Laurent Fischer, M.D..
Is Adverum Biotechnologies publicy listed? Yes, Adverum Biotechnologies is a public company listed on NAS.
What is the stock symbol of Adverum Biotechnologies? Adverum Biotechnologies trades under ADVM ticker.
When did Adverum Biotechnologies go public? Adverum Biotechnologies went public in 2014.
Who are competitors of Adverum Biotechnologies? Similar companies to Adverum Biotechnologies include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Adverum Biotechnologies? Adverum Biotechnologies's current market cap is $71.4M
What is the current revenue of Adverum Biotechnologies? Adverum Biotechnologies's last 12-month revenue is $0.7M.
What is the current EBITDA of Adverum Biotechnologies? Adverum Biotechnologies's last 12-month EBITDA is -$124M.
What is the current EV/Revenue multiple of Adverum Biotechnologies? Current revenue multiple of Adverum Biotechnologies is -12.1x.
What is the current EV/EBITDA multiple of Adverum Biotechnologies? Current EBITDA multiple of Adverum Biotechnologies is 0.1x.
Is Adverum Biotechnologies profitable? Yes, Adverum Biotechnologies is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.